Omeros is a biotech firm developing and commercializing therapies for rare diseases, with a focus on complement-mediated disorders, addiction, and cancer.
The company has no approved products generating revenue; recent quarterly revenue was $0.03B, but net income was only $0.01B, and annual operating losses were around $0.12B-$0.17B.
Omeros faces competition from larger biotech firms like Alexion and Novartis in complement inhibition. Its lead drug, narsoplimab, is not yet approved, and the pipeline is early-stage, so the moat is weak.
Key events, in time order
None yet
None yet
The post links to an article about Omeros Corporation, a biopharmaceutical company focused on therapies for rare diseases. The nature of the discussion is informational, providing a link to external content.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
